Genomic Test may Predict Aggressive Disease in Men Newly Diagnosed with Prostate Cancer

Written By : Hina Zahid

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2021-07-28 03:30 GMT | Update On 2021-07-28 08:20 GMT

After a biopsy comes back positive for prostate cancer, patients and their doctors are often left with a choice between taking a watch-and-wait approach, known as active surveillance, or proceeding with surgery or radiation.

And identifying which patients will benefit from more immediate and aggressive treatment isn't always clear.

A new, University of Michigan-led study analyzing data from more than 850 patients across the state of Michigan, however, found a commercially available genomic test known as Decipher Biopsy may help identify patients who are at high risk of cancer progression.

"We have long needed better tools to reduce the uncertainty of these initial treatment decisions," said study first author Randy Vince, Jr., M.D., M.S., an oncology fellow at U-M.

Veracyte, the company that makes the tests, did not sponsor the study or play a role in the analysis.

Between February 2015 and October 2019, 855 patients participating in the state Michigan Urological Surgery Improvement Collaborative registry underwent testing with the Decipher Biopsy test after being diagnosed with prostate cancer — one of the first real- world, observational studies of a commercially available genomic test designed to aid in decision-making after an initial diagnosis.

The research team found the data supported the clinical utility of the Decipher Biopsy test, according to findings published in Prostate Cancer and Prostatic Diseases.

The analysis found men with a high Decipher score who were placed on active surveillance had a shorter time before active treatment was needed, Vince said. And for those who underwent surgery to remove the prostate gland, high scores were associated with shorter time until their prostate-specific antigen (PSA) levels went up again or when they were put on anti-androgen therapy..

https://www.nature.com/articles/s41391-021-00428-y

Article Source : Prostate Cancer and Prostatic Diseases

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Hina Zahid

Hina Zahid Joined Medical Dialogue in 2017 with a passion to work as a Reporter. She coordinates with various national and international journals and association and covers all the stories related to Medical guidelines, Medical Journals, rare medical surgeries as well as all the updates in the medical field. Email: editorial@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Genomic Test may Predict Aggressive Disease in Men Newly Diagnosed with Prostate Cancer

Similar News

Millions of men could benefit from faster scan to diagnose prostate cancer: JAMA

SOX2: a key player in prostate cancer progression and treatment resistance: Study

Steroidal MRAs Ineffective and Risky in Kidney Transplant Recipients: Study

Penile Implant Satisfaction Drops in Prostate Cancer Patients on Hormonal Treatment, reveals study

JnJ bags USFDA nod for bladder cancer treatment Inlexzo

Why male embryos grow faster: Study reveals genetic clues

Protein deficiency during pregnancy and lactation may compromise sperm viability in offspring: Study

Urinary NGAL Emerges as a Reliable Biomarker in Nephrotic Syndrome: Study Finds